1 month ago
19
Soumya Eswaran
Fri, February 6, 2026 astatine 7:26 AM CST 3 min read
Baron Funds, an concern absorption company, released its fourth-quarter capitalist missive for the “Baron Health Care Fund”. A transcript of the missive tin beryllium downloaded here. The money roseate 13.10% (Institutional Shares) successful the quarter, compared to a 11.92% summation for the Russell 3000 Health Care Index (benchmark) and a 2.40% summation for the Russell 3000 Index (the Index). The Fund returned 10.28% for the afloat year, compared to 14.56% and 17.15% gains for the indexes, respectively. Strong banal enactment successful biotechnology contributed to the Fund’s comparative gains successful the quarter. The Fund seeks to put successful businesses with secular maturation opportunities, a sustainable competitory edge, and beardown management. The steadfast believes that healthcare is simply a beardown assemblage successful the U.S. economy, offering charismatic concern opportunities with affirmative momentum heading into 2026. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2025.
In its fourth-quarter 2025 capitalist letter, Baron Health Care Fund highlighted Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) arsenic a caller summation to the portfolio. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is simply a biotechnology institution that focuses connected processing treatments for dermatological diseases. On February 5, 2026, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) banal closed astatine $26.07 per share. One-month instrumentality of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) was -7.62%, and its shares are up 124.55% implicit the past 12 months. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has a marketplace capitalization of $3.193 billion.
Baron Health Care Fundstated the pursuing regarding Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) successful its 4th fourth 2025 capitalist letter:
"We bought shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a biotechnology institution that sells Zoryve pick and foam for the attraction of autoimmune dermatologic conditions. Topical Zoryve is utilized for patients with mild-moderate illness and tin beryllium utilized successful operation with biologic treatments (such arsenic Dupixent and Rinvoq) for moderate-severe disease. The modular of attraction for these patients contiguous is intermittent courses of steroids. Zoryve appears to person akin efficacy to steroids, but has less broadside effects and tin beryllium utilized chronically successful a elemental regular regimen. Although topical dermatology drugs person historically had a pugnacious clip securing bully security access, Arcutis launched Zoryve astatine a tenable terms and payers person recognized the worth Zoryve provides, and 80% of patients with commercialized security present person access. In total, Zoryve’s existent approved indications people 30 cardinal patients successful the U.S., of which 19 cardinal person already been prescribed a topical medication. Assuming mean adoption (20% to 25% stock of topical prescriptions) wrong the conception of physicians that Arcutis targets gets america to $3 cardinal positive of highest sales. Arcutis is already escaped currency travel affirmative and should spot meaningful operating leverage successful the coming years. With 90% gross margins, Arcutis should yet make precise precocious operating margins."
English (CA) · 
English (US) · 
Spanish (MX) ·